R&D LSX2026: On a therapeutic vision for ocular disease, with Al... Alexander Gebauer, co-founder & executive chairman of Galimedix Therapeutics, discusses transforming treatment of major neurodegenerative eye diseases
R&D BIO-Europe Spring 2026: In conversation with Robert Jacks Robert Jacks, CEO of Sparrow Pharmaceuticals, discusses the company’s work in the cardiometabolic space.
R&D Treating the chronic diseases GLP-1s miss, with Laurent Auda... Prive Bio CEO Laurent Audaly spoke with pharmaphorum during the JP Morgan Healthcare conference, discussing GLP-1s in the cardiometabolic space.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
R&D DNA as a programmable language, with Adrian Woolfson and Kai... A new technology just announced this weekend in a paper in Nature could have a radical impact on how gene assembly is carried out.
News Sandoz says it is entering "golden decade" in biosimilars Sandoz said today it intends to double net sales between 2025 and 2035, fuelled by an acceleration in biosimilar medicine development.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.